- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06194591
Nephrospec Switzerland
Low-intensity Extracorporeal Shockwave Therapy With the Nephrospec TM Device for the Treatment of Hypertension in Patients Diagnosed With Chronic Kidney Disease (CKD) : a Randomized, Double-blind Sham-controlled Monocentric Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind sham-controlled monocentric trial. Adult patients that are diagnosed with hypertension (systolic blood pressure 140 - 180 mmHg), currently on stable (over 60 days) medical therapy and with moderate to severe chronic kidney disease (eGFR 20-60 mL/min/1.73m2) who are currently on stable (at least 60 days) medical therapy are included in this trial.
20 patients are randomized into the active treatment arm with the investigational medical device, 10 patients into the sham arm. Low-intensity extracorporal shock wave (Li-ESWT) sessions (arm1) with a dedicated probe (Nephrospec device) or sham sessions (arm2), within three consecutive weeks, will be applied to the kidneys of patients. Patients will be followed-up for 48 weeks after the treatment.The study includes a third arm (arm3) in which treatment sessions are administered to patients that were in the placebo group in the first phase of the study and for whom their condition did not improve (arm 2).
Low-intensity extracorporeal shockwave therapy (Li-ESWT) is based on the classic technique of lithotripsy for the extracorporeal treatment of kidney stones but applied at much lower intensity (~10%). Previous histological studies in animals have shown that Li-ESWT has favourable effects on kidney perfusion and oxygenation. In human studies that included patients with diabetic nephropathy, six to twelve sessions of Li-ESWT lead to long-term reduction of blood pressure and stabilization of renal function (eGFR). The medical device Nephrospec TM is CE-mark and used in the ambulatory setting to lower BP in patients with CKD. The device will be used according to the instructions and indications mentioned in the operator manual.
The primary outcome of this trial is the change in systolic 24-hour ambulatory blood pressure (ABPM) from baseline to 12 weeks post treatment. Further important secondary ouctomes are automatic office blood pressure (AOBP), the change in number or dose of blood pressure medications, the change in eGFR and the change in albumine/creatinine ratio (ACR). Furthermore, the study will assess whether the treatment improves renal function, Contrast enhanced ultrasound (CEUS)-assessed perfusion index, as well as renal oxygenation and fibrosis (ADC) assessed by MRI.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Menno Pruijm, Dr
- Phone Number: +41 (0)21 314 13 58
- Email: menno.pruijm@chuv.ch
Study Contact Backup
- Name: Tanguy Corre
- Email: tanguy.corre@unisanrte.ch
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Recruiting
- Department of Nephrology, Centre Hospitalier Universitaire Vaudois
-
Contact:
- Menno Pruijm, Dr
- Phone Number: 0041795565946
- Email: menno.pruijm@chuv.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 years to 80 years.
- Patient is diagnosed with Hypertension, i.e. office systolic blood pressure ≥140 mmHg (as per AHA/ACC guidelines, 2017), currently on stable (over 60 days) medical therapy as prescribed by a physician, of none, one, or more antihypertensive medication classes. Patients will be considered stable if no relevant medication change for over 60 days or for 30 days if there were no previous changes 90 days before the current change.
- Patients diagnosed with moderate to severe chronic renal failure (eGFR 20-60 mL/min/1.73m2) who are currently on stable medical therapy as prescribed by a physician.
- Patient is able and willing to comply with the required follow-up schedule.
- Patient is capable of giving an informed consent.
Exclusion Criteria:
- Hypertension: Individual's systolic BP is over 180mmHg when receiving stable medical medication regimen as prescribed by a physician, of none, one, or more antihypertensive medication classes at maximally tolerated dose. Hypertension secondary to an identifiable and treatable cause, other than Renal artery stenosis or CKD, or is prescribed a medication that may raise BP.
- History of previous renal artery stent. Stent or other intervention involving renal arteries including but not limited to renal denervation procedures.
- Kidney conditions non compatible with the study: Patient has an eGFR <20 ml/min/1.73m², is on Dialysis or has had a kidney transplant performed. Active pyelonephritis. History of or current kidney stones. Patients with polycystic kidney disease or a known complicated renal cyst (Bosniak III or higher).
- Symptomatic patients (Macrohematuria) with a decrease of over 2 grams in Hb.
- Hemoglobin (Hb) ≤ 9 grams per deciliter (blood).
- Coagulation issues: Bleeding tendency resulting from hematologic disease. Subjects having INR > 2.5 and PT, PTT and platelet count which deviates from the clinical laboratory normal reference range.
- Diseases non compatible with the study: Recent (less than 6 months) history of myocardial infarction, PCI, stroke or hospitalization for HFrEF (heart failure with reduced ejection fraction). Individual has type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c > 10%).
- Active Cancer - primary tumor or metastatic, such as liver, renal, testicular, abdominal tumor or local tumor at treatment area..
- Treatment non compatible with the study: Patients that have been treated with immunosuppression in the last 3 months. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. No change in dosing of RAS inhibitors in the month prior to the procedure is required.
- Technical impossibility to participate: Local infection of the skin at the area to be in contact with the applicator.
- Known allergy to Sonovue® contrast product (hypersensibility to sulfur hexyfluoride or another component).
- No other contraindication to SonoVue, ie. patients with right-to-left shunts, severe pulmonary hypertension (pulmonary arterial pressure > 90 mm Hg), uncontrolled systemic hypertension and in adult patients with respiratory distress syndrome (ARDS).
- Contraindication to undergo MR-imaging such as the presence of a pacemaker or other implanted metallic device or severe claustrophobia.
- Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject/ Unable to obtain consent
- Known or suspected non-compliance, drug or alcohol abuse
- Individual works night shifts.
- Individual is pregnant, breast feeding or planning to become pregnant.
- Individual does not want to be informed in case of accidental finding related to individual's health discovered during imaging or other study-related exams.
- Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation,
- Previous enrolment into the current investigation,
- Enrolment of the PI, his/her family members, employees, and other dependent persons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Stage A - Active treatment
The medical device NephrospecTM is used to administer 6 treatments of Low-intensity extracorporeal shockwave therapy (Li-ESWT) to the kidneys during 3 weeks.
|
Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week. Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter. |
Sham Comparator: Stage A - Sham treatment
The sham group will undergo the same treatment schedule, but with an applicator with an internal barrier to prevent shockwaves to pass through to the patient.
|
The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
|
Active Comparator: Stage B - Open label active treatment
Patients that were in the placebo group of stage A and do not exhibit a significant improvement in one of the main parameters will be eligible to enter stage B where they are treated with the active device in an open-label fashion.
|
Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week. Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic 24-hour ambulatory blood pressure (ABPM)
Time Frame: Baseline to 12-weeks (-1/+3weeks) Follow-up post last treatment.
|
Assess the Systolic 24-hour ambulatory blood pressure depending on the particpant's arm affiliation
|
Baseline to 12-weeks (-1/+3weeks) Follow-up post last treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
attended Automatic Office Blood Pressure
Time Frame: baseline to 4 weeks (+3 weeks), 24 weeks (±3 weeks) and 48 weeks (±3 weeks) post last treatment
|
Assess the attended Automatic Office Blood Pressure depending on the particpant's arm
|
baseline to 4 weeks (+3 weeks), 24 weeks (±3 weeks) and 48 weeks (±3 weeks) post last treatment
|
unattended Automatic Office Blood Pressure
Time Frame: from baseline to 4 weeks (+3 weeks), 24 weeks (±3 weeks) and 48 weeks (±3 weeks) post last treatment
|
Assess the unattended Automatic Office Blood Pressure depending on the particpant's arm
|
from baseline to 4 weeks (+3 weeks), 24 weeks (±3 weeks) and 48 weeks (±3 weeks) post last treatment
|
Number, dose or number of medications to maintain blood pressure control
Time Frame: baseline to 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment
|
Assess the number, dose or number of medications to maintain blood pressure control depending on the particpant's arm
|
baseline to 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment
|
Serum creatinine levels / eGFR - calculated by CKD - EPI
Time Frame: baseline to 4 weeks (+3 weeks), 12 weeks (-1/+3 weeks), 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment.
|
Assess the serum creatinine levels / eGFR (calculated by CKD - EPI) depending on the particpant's arm
|
baseline to 4 weeks (+3 weeks), 12 weeks (-1/+3 weeks), 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment.
|
Albumin/creatinine ratio (ACR)
Time Frame: baseline to 4 weeks (+3 weeks), 12 weeks (-1/+3 weeks), 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment.
|
Assess the albumin/creatinine ratio (ACR) depending on the particpant's arm
|
baseline to 4 weeks (+3 weeks), 12 weeks (-1/+3 weeks), 24 weeks (±3 weeks), and 48 weeks (±3 weeks) post last treatment.
|
CEUS-assessed Perfusion Index (PI)
Time Frame: baseline to 12 weeks (±3 weeks)
|
Assess the CEUS-assessed Perfusion Index (PI) depending on the particpant's arm
|
baseline to 12 weeks (±3 weeks)
|
MRI-assessed oxygenation (R2*), fibrosis (ADC) and Phase-contrast
Time Frame: baseline to 12 weeks (±3 weeks)
|
Assess the MRI-assessed oxygenation (R2*), fibrosis (ADC) and Phase-contrast depending on the particpant's arm
|
baseline to 12 weeks (±3 weeks)
|
Plasma renin activity
Time Frame: baseline to 12 weeks (±3 weeks)
|
Assess the plasma renin activity depending on the particpant's arm
|
baseline to 12 weeks (±3 weeks)
|
Plasma aldosterone levels
Time Frame: baseline to 12 weeks (±3 weeks)
|
Assess the plasma aldosterone levels depending on the particpant's arm
|
baseline to 12 weeks (±3 weeks)
|
Cystatin C levels
Time Frame: baseline to 12 weeks (±3 weeks)
|
Assess the cystatin C levels depending on the particpant's arm
|
baseline to 12 weeks (±3 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Menno Pruijm, Dr, CHUV
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hypertension
- Kidney Diseases
- Renal Insufficiency, Chronic
Other Study ID Numbers
- 2023-D0075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on NephrospecTM, low-intensity extracorporal shockwave therapy device
-
Institute for the Study of Urological Diseases,...CompletedChronic Pelvic Pain Syndrome | Chronic Non-bacterial Prostatitis Type IIIBGreece
-
The Methodist Hospital Research InstituteRecruitingErectile Dysfunction Following Radical ProstatectomyUnited States
-
Northwell HealthEnrolling by invitationErectile DysfunctionUnited States
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Hospital Authority, Hong KongNot yet recruitingErectile Dysfunction
-
Herlev HospitalWithdrawnChronic Pelvic PainDenmark
-
Rambam Health Care CampusUnknown
-
Odense University HospitalUnknownErectile Dysfunction | Radical Prostatectomy | Extracorporeal Shockwave TherapyDenmark
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Chang Gung Memorial HospitalUnknown